A study of biomarker predicting the effect of Nivolumab for unresectable advanced or recurrent gastric cancer.
Not Applicable
Recruiting
- Conditions
- nresectable advanced or recurrent gastric cancer
- Registration Number
- JPRN-UMIN000032164
- Lead Sponsor
- Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Synchronous or metachronous (within 5 years) double cancers, except for intraepithelial tumor (Carcinoma in situ) or intramucosal tumor curatively resectable by local therapy at the time of Nivolumab treatment. 2) History of medical therapy for the purpose of the immune checkpoint inhibitors such as antiPD-1 antibody, antiPD-L1 antibody, antiCTLA-4 antibody or other T cell regulator before the Nivolumab treatment. 3) Having severe psychological illness and difficult to make a judgement for participation in the study. 4) Judged to be unfit to participate in the study by investigater.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association between overall survival (OS) and the protein expression of each factor.
- Secondary Outcome Measures
Name Time Method